Media stories about Immune Design (NASDAQ:IMDZ) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Immune Design earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.3262647682619 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
IMDZ stock traded up $0.05 on Friday, hitting $3.80. The company had a trading volume of 158,200 shares, compared to its average volume of 425,662. Immune Design has a 12-month low of $2.80 and a 12-month high of $13.05. The stock has a market capitalization of $180.47 million, a P/E ratio of -2.17 and a beta of 1.88.
Immune Design (NASDAQ:IMDZ) last issued its earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. The company had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $1.83 million. Immune Design had a negative net margin of 2,352.98% and a negative return on equity of 52.00%. analysts predict that Immune Design will post -1.27 EPS for the current year.
A number of equities research analysts have recently commented on IMDZ shares. Zacks Investment Research upgraded shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Tuesday, March 13th. Jefferies Group restated a “buy” rating and issued a $8.00 target price on shares of Immune Design in a report on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.63.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.